Adlyxin, Lyxumia
Evidence Grade A — Regulatory approved. 693 published studies. 56 registered clinical trials.
Loading...
Lixisenatide (sold as Adlyxin) is a once-daily injectable GLP-1 treatment for type 2 diabetes that primarily works by slowing the rate at which food leaves the stomach, making it particularly effective at controlling blood sugar spikes after meals. As a standalone product, it has been largely overtaken by more powerful alternatives, but it continues in use as part of the combination product Soliqua (lixisenatide plus insulin glargine).
693 published studies: 467 human, 36 animal, 14 in-vitro, 276 reviews
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide.
Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Lixisenatide targets the same GLP-1 receptor as other medications in this class, but because it is shorter-acting, its main effect is dramatically slowing the rate at which food leaves the stomach. This flattens the blood sugar spike that typically follows a meal. It also promotes some insulin release and reduces glucagon, but these effects are less pronounced than with longer-acting GLP-1 treatments. This makes lixisenatide particularly suited for people whose main challenge is post-meal blood sugar control rather than overall blood sugar levels.
Lixisenatide's main contribution to the evidence base was the ELIXA trial — the first cardiovascular outcomes study completed for any GLP-1 medication, involving over 6,000 patients. It showed a neutral cardiovascular profile (neither harmful nor beneficial), which was adequate for safety but did not match the heart benefits later demonstrated by semaglutide, liraglutide, and dulaglutide. As a standalone agent, lixisenatide was discontinued from the US market because it offered limited advantages over newer, more effective GLP-1 treatments. Its ongoing relevance is as the GLP-1 component in the Soliqua combination product, where its ability to control post-meal blood sugar spikes complements the all-day fasting glucose coverage provided by insulin glargine — addressing two different parts of the blood sugar problem in a single daily injection.
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
The Effect of Lixisenatide on the Effect of Pituitary Hormones
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
EMA Marketing Authorisation
FDA ORIG 1
FDA SUPPL 2
FDA SUPPL 3
Health Canada Market Authorisation
FDA SUPPL 7
FDA SUPPL 9
FDA SUPPL 8
FDA SUPPL 11
FDA SUPPL 12
FDA SUPPL 13
FDA SUPPL 14
FDA SUPPL 18
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
Octreotide is marketed as Sandostatin (approved 1988), Sandostatin LAR monthly depot (approved 1998), and Mycapssa oral capsules (approved June 2020 — the first oral somatostatin analogue). It is used for acromegaly, carcinoid syndrome, VIPomas, and gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The PROMID trial demonstrated that octreotide LAR significantly delayed tumour progression in patients with neuroendocrine tumours of the midgut, establishing somatostatin analogues as a standard treatment for these cancers. The approval of Mycapssa as an oral formulation was a significant advance for patients who had been receiving monthly injections for years. Octreotide has been on the market for over 35 years and has one of the longest safety track records of any peptide medication.
